Health Indicator Report of Invasive Pneumococcal Disease - Persons Aged 65 Years and Older
''Streptococcus pneumoniae'' (pneumococcus) remains a leading infectious cause of serious illness, including bacteremia, meningitis, and pneumonia, among older adults in the United States. Use of a 7-valent pneumococcal conjugate vaccine (PCV7) since 2000 and PCV13 since 2010 among children in the United States has reduced pneumococcal infections directly and indirectly among children, and indirectly among adults. By 2013, the incidence of invasive pneumococcal disease (IPD) caused by serotypes unique to PCV13 among adults aged 65 years and older had declined by approximately 50% compared with 2010, when PCV13 replaced PCV7 in the pediatric immunization schedule. However, in 2013 an estimated 13,500 cases of IPD occurred among adults aged 65 years and older. Approximately, 20% to 25% of IPD cases and 10% of community-acquired pneumonia cases in adults aged 65 years and older are caused by PCV13 serotypes and are potentially preventable with the use of PCV13 in this population. Additionally, New Mexico consistently has higher rates of IPD among adults aged 65 years and older when compared to national rates. The greatest burden of disease is seen in the American Indians/Alaska Natives (AIAN). The rate of disease among AIAN adults aged 65 years and older in 2013 was 137.6 per 100,000 compared to 34.1 per 100,000 among non- AIAN adults aged 65 years and older.
- New Mexico Data Source, 2006 and later: New Mexico Electronic Disease Surveillance System (NM-EDSS), Infectious Disease Epidemiology Bureau, New Mexico Department of Health.
- Population Estimates: University of New Mexico, Geospatial and Population Studies (GPS) Program, http://gps.unm.edu/.
Data Interpretation IssuesThe rate of ''S. pneumoniae'' cases might be affected by healthcare access, healthcare testing practices, laboratory testing capacity, reporting practices, and/or surveillance deficiencies.
DefinitionRate per 100,000 of invasive pneumococcal disease in adults aged 65 years and older in New Mexico. Number of ''Streptococcus pneumoniae'' in New Mexico adults aged 65 years and older divided by the population of New Mexico residents adults aged 65 years and older x 100,000.
NumeratorThe number of invasive, culture-confirmed cases of ''Streptococcus pneumoniae'' in adults aged 65 years and older in New Mexico in one calendar year time.
DenominatorPopulation of New Mexico resident adults aged 65 years and older in one calendar year time period.
Healthy People Objective: IID-4.2, New invasive pneumococcal infections among adults aged 65 years and olderU.S. Target: 31 new cases per 100,000 adults aged 65 years and older
Other ObjectivesNew Mexico Community Health Status Indicator (CHSI)
How Are We Doing?Rates of IPD have decreased across all ages, including those adults aged 65 years and older, since the introduction of PCV7 in children in 2000 and PCV13 in 2010.
How Do We Compare With the U.S.?While both the national and New Mexico rates of IP in adults aged 65 years and older are dropping, New Mexico has consistently had higher rates of IPD. In 2013, the rate of IPD adults aged 65 years and older in New Mexico was 39.5 per 100,000. The US rate was lower at 23.9 per 100,000 population.
What Is Being Done?On August 13, 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) among adults aged 65 years and older. PCV13 should be administered in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax23, Merck & Co., Inc.]), the vaccine currently recommended for adults aged 65 years and older. Additionally, New Mexico is one of ten national sites that participates in the Centers for Disease Control and Prevention (CDC) Emerging Infectious Programs (EIP), Active Bacterial Core Surveillance (ABCs) which includes conducting active population-based surveillance for invasive ''Streptococcus pneumoniae''. Also, as a part of the CDC EIP ABCs network, New Mexico is participating in a study evaluating the effectiveness of PCV13 in adults aged 65 years and older.
Page Content Updated On 08/25/2017, Published on 08/30/2017